Beam Therapeutics

Company Overview

Beam Therapeutics is a biotechnology company dedicated to creating the leading, fully integrated platform for precision genetic medicines. The company has developed a platform with a suite of gene editing and delivery technologies and internal manufacturing capabilities.

Beam Therapeutics’ gene editing technologies are centered around their proprietary base editing technology, which offers a unique class of precision genetic medicines that target a single base in the genome without causing a double-stranded break in the DNA. This method utilizes a chemical reaction to create precise, predictable, and efficient genetic outcomes at the desired sequence. Their proprietary base editors consist of two main components: (i) a CRISPR protein bound to a guide RNA that targets DNA without causing a double-stranded break, and (ii) a base editing enzyme, such as a deaminase, which performs the desired chemical modification of the target DNA base. The company is also exploring various delivery methods tailored to tissue types, including ex vivo and in vivo approaches.

Financial Highlights (FY 2024)

Company's Business Segments

• License and Collaboration Agreements : License and collaboration represents revenue recorded under the Lilly, Pfizer, Apellis, Orbital and Verve Agreements